We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Age-Related Eye Disease Study 2 formulation (lutein, zeaxanthin, vitamin C, vitamin E, zinc, copper)
The one supplement formula with randomised-trial evidence for slowing age-related macular degeneration — but only in people who already have intermediate AMD or advanced AMD in one eye. It does not prevent AMD, and it does not restore vision that has been lost. AREDS2's own contribution was to swap beta-carotene out, because beta-carotene raises lung cancer risk in smokers and former smokers.
What the evidence says
Most AREDS2 Formula studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 1994–2025 with a typical study size of 4,203 participants.
Based on 14 studies · 2 meta-analyses · 8 RCTs · 76,001 total participants
Confidence
High confidenceBy outcome
1 more outcome with fewer studies not shown.
For one narrow population — people with intermediate AMD, or advanced AMD in one eye — this is among the best-evidenced supplements in medicine, with a large randomised trial, a 10-year follow-up and moderate-certainty Cochrane support. The score is held at 7 rather than higher because the AREDS2 additions themselves (lutein/zeaxanthin, omega-3) were null in the primary analysis, the effect does not extend to prevention, and no trial has shown restored vision.
No trials currently enrolling · 4 completed on ClinicalTrials.gov
1 of the completed trials have posted results
Registered trials show research momentum for AREDS2 Formula, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Sep 2026
Our research database did not respond in time, so the studies and count above cover only our curated set. This refreshes automatically.
This is a two-generation product and the distinction matters.
The original AREDS formula (vitamin C 500 mg, vitamin E 400 IU, beta-carotene 15 mg, zinc 80 mg, copper 2 mg) was tested in 3,640 people and cut the odds of progressing to advanced AMD by roughly a quarter (OR 0.72, 99% CI 0.52-0.98) — the benefit concentrated in participants who already had large drusen or advanced AMD in one eye.
Participants with only small drusen had a 1.3% five-year progression risk and nothing to gain. AREDS2 then enrolled 4,203 people to ask whether adding lutein/zeaxanthin or omega-3 improved on that, and whether beta-carotene could be removed.
The honest answer to the first question is no: in the primary analysis lutein/zeaxanthin did not further reduce progression (HR 0.90, 98.7% CI 0.76-1.07, P=.12), nor did DHA+EPA (HR 0.97). Omega-3 was dropped from the formula for exactly that reason.
The answer to the second question is what made AREDS2 the standard of care. Beta-carotene is an established lung-cancer hazard in smokers — ATBC found 18% more lung cancer in 29,133 male smokers, and CARET was stopped 21 months early with a relative risk of 1.28 in smokers, former smokers and asbestos workers.
AREDS2 saw the same signal in its own cohort (23 lung cancers vs 11, mostly in former smokers), and at 10-year follow-up the odds ratio for lung cancer was 1.82 (95% CI 1.06-3.12) for beta-carotene versus 1.15 (0.79-1.66) for lutein/zeaxanthin.
Lutein/zeaxanthin was therefore a safe substitute rather than a proven upgrade — though in the direct head-to-head it did beat beta-carotene for late AMD (HR 0.85, 95% CI 0.73-0.98 at 10 years).
AREDS2 also tested a lower zinc dose, 25 mg instead of 80 mg, and found no meaningful difference (HR 1.04, 95% CI 0.94-1.14) — relevant because 80 mg is far above the 25 mg EFSA tolerable upper intake and is the reason 2 mg of copper is in the formula at all.
What the formula does not do is equally well established: it does not prevent AMD in people who don't have it, it did not reduce cataract surgery, and it had no effect on cognitive function.
Lutein and zeaxanthin are the carotenoids that concentrate in the macula, and supplementation measurably raises macular pigment optical density — a 2024 network meta-analysis of 38 randomised trials found every antioxidant combination tested increased MPOD, with lutein + zeaxanthin + fatty acid ranked highest (SUCRA 99.3%). AREDS2 chose them partly on this basis, describing lutein and zeaxanthin as important components of the retina. Note the gap: raising macular pigment is a reliable biomarker effect, but AREDS2's primary clinical analysis was null, so the biomarker did not translate into a further reduction in AMD progression.
The stated rationale for the original AREDS formula was that antioxidants may prevent cellular damage in the retina by reacting with free radicals produced during light absorption. This is the hypothesis the trial was built to test — it was supported at the outcome level (antioxidants plus zinc reduced progression) but the mechanism itself was never directly demonstrated in these trials, and antioxidants alone were not statistically significant (OR 0.80, 99% CI 0.59-1.09).
Zinc was tested as a separate factor in AREDS at 80 mg as zinc oxide. Zinc alone came close to significance for advanced AMD (OR 0.75, 99% CI 0.55-1.03) and reached it in the higher-risk subgroup (OR 0.71, 99% CI 0.52-0.99), while antioxidants alone did not — the combination is what met the trial's threshold. In the 10-year follow-up, mortality was reduced in participants assigned to zinc, especially death from circulatory disease.
The formula contains 2 mg copper as cupric oxide alongside 80 mg zinc. High zinc intake causes zinc-induced copper deficiency, with anaemia and neutropenia among the recognised consequences; the EFSA tolerable upper intake for zinc is 25 mg/day and the FDA figure is 40 mg/day, both far below the AREDS dose. Copper is a countermeasure, not an active ingredient — no trial has shown copper itself does anything for AMD.
Beta-carotene is not neutral in smokers. ATBC randomised 29,133 male smokers and found 18% more lung cancer (95% CI 3-36%) with beta-carotene; CARET randomised 18,314 smokers, former smokers and asbestos workers to beta-carotene plus retinol and was stopped 21 months early with a lung cancer relative risk of 1.28 (95% CI 1.04-1.57). AREDS2 saw the same pattern internally and at 10 years measured a lung cancer odds ratio of 1.82 for beta-carotene assignment. Lutein/zeaxanthin was substituted because it carries no such signal (OR 1.15, 95% CI 0.79-1.66).
How AREDS2 Formula works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
This is the single most important safety point on the page. Use the AREDS2 formulation and never the original beta-carotene version. In AREDS2 itself the excess lung cancers occurred mostly in FORMER smokers, and at 10 years beta-carotene assignment carried a lung cancer odds ratio of 1.82 (95% CI 1.06-3.12). Having quit does not remove the risk. Lutein/zeaxanthin showed no such signal (OR 1.15, 0.79-1.66).
There is no reason to take this. Cochrane rates the failure of these individual antioxidants to prevent AMD as high-certainty; the pooled 76,756 spans five trials and all comparisons, with vitamin E tested in 55,614 and beta-carotene in 22,083 (men only), and in AREDS itself the low-risk participants — extensive small drusen, non-extensive intermediate drusen, or pigment changes — had a 1.3% five-year risk of progression, so the 1,063 of them contributed nothing to the benefit. Get a dilated eye exam and let the retinal findings decide.
The formula slows progression; it does not reverse it. Every outcome in AREDS and AREDS2 was about developing advanced AMD or losing further acuity, never about regaining vision. Where advanced AMD is present in one eye, the trial evidence applies to protecting the other eye.
CARET included asbestos-exposed workers alongside smokers, and the beta-carotene plus retinol combination raised lung cancer risk (RR 1.28, 95% CI 1.04-1.57) enough to stop the trial 21 months early. Avoid any beta-carotene-containing eye formula.
The 400 IU of vitamin E deserves a conversation with your prescriber. One trial in the Cochrane prevention review reported an excess of haemorrhagic strokes on vitamin E (HR 1.74, 95% CI 1.04-2.91, low-certainty evidence), and ATBC found more haemorrhagic-stroke deaths in the alpha-tocopherol arm.
This formula will not do that. The AREDS2 cognitive substudy tested 3,501 participants over 5 years with validated cognitive batteries and found no significant difference in any supplement arm. Choose it for your retina, not your brain.
The formula already supplies 80 mg of zinc, more than three times the 25 mg EFSA tolerable upper intake and double the 40 mg FDA figure. Stacking another zinc product pushes intake into the range where zinc-induced copper deficiency, anaemia and neutropenia are documented. Do not add zinc on top.
The 2 mg of cupric oxide in the formula is calibrated to offset the 80 mg zinc load, not to correct a deficiency. Adding a separate copper supplement without a measured deficiency has no evidence behind it and unbalances a combination that was tested as a unit.
The formula contains 400 IU of vitamin E. Cochrane's AMD-prevention review recorded an excess of haemorrhagic strokes in a vitamin E arm (39 versus 23 events, HR 1.74, 95% CI 1.04-2.91, low-certainty evidence), and ATBC likewise reported more deaths from haemorrhagic stroke with alpha-tocopherol. Discuss with your prescriber before combining.
High-dose zinc and copper are divalent cations that chelate these antibiotics and reduce their absorption. Separate the supplement from the antibiotic dose; ask your pharmacist for the interval appropriate to the specific drug.
The formula deliberately supplies copper, which directly opposes chelation therapy, and zinc itself is used therapeutically in copper-overload disease. Anyone on copper-directed treatment needs their specialist to decide, not an over-the-counter product.
Zinc at 80 mg competes with iron for absorption at the shared divalent-cation transporters. Separate the doses by a few hours if you take both.
Tip: Driven by the 80 mg zinc dose. Take with a meal and split the daily amount across two servings; a 25 mg zinc version performed no differently in AREDS2 (HR 1.04, 95% CI 0.94-1.14) and is a reasonable switch
Tip: The recognised consequence of intake above the tolerable upper level. The 2 mg of copper in the formula is the built-in countermeasure — never take an AREDS-style zinc dose without it, and do not add extra zinc from other products
Tip: A harmless cosmetic effect of carotenoid intake that reverses on stopping. Not a reason to discontinue
Tip: AREDS reported no statistically significant serious adverse effect associated with any of its formulations, and the 10-year follow-up likewise reported no adverse effects associated with the AREDS formulation — with the crucial exception of the beta-carotene lung cancer signal, which is the reason the formula was changed
Tip: Reported in the original AREDS trial with high-dose zinc; AREDS2 saw no difference between 80 mg and 25 mg zinc arms. Raise urinary symptoms with your clinician rather than stopping unsupervised.
AREDS2 Formula has an evidence score of 7/10 — strong evidence based on 14 indexed studies, including 2 meta-analyses. The one supplement formula with randomised-trial evidence for slowing age-related macular degeneration — but only in people who already have intermediate AMD or advanced AMD in one eye. It does not prevent AMD, and it does not restore vision that has been lost. AREDS2's own contribution was to swap beta-carotene out, because beta-carotene raises lung cancer risk in smokers and former smokers. Representative study: PMID 28756617.
The commonly studied dose of AREDS2 Formula is One AREDS2 daily regimen, usually split into two servings: vitamin C 500 mg, vitamin E 400 IU, lutein 10 mg, zeaxanthin 2 mg, zinc 80 mg (as zinc oxide) and copper 2 mg (as cupric oxide). Individual needs vary — start at the lower end of the range and adjust based on how you respond.
The best time to take AREDS2 Formula is with meals. Take it with food. Vitamin E and the carotenoids lutein and zeaxanthin are fat-soluble and absorb better with a meal containing fat, and taking the 80 mg zinc dose with food substantially reduces the nausea that is the commonest reason people abandon the formula.
AREDS2 Formula is generally safe at recommended doses, with a few precautions worth noting. The most commonly reported side effects are nausea and stomach upset, zinc-induced copper deficiency, with anaemia and neutropenia, genitourinary problems (men, zinc-related). Use caution if any of these apply to you: The ORIGINAL AREDS formula (containing beta-carotene) in anyone who currently smokes or has ever smoked — beta-carotene increased lung cancer incidence in ATBC (+18%) and CARET (RR 1.28), and doubled 10-year lung cancer odds in AREDS2 itself (OR 1.82); Concurrent use with other beta-carotene or high-dose vitamin A supplements in smokers and former smokers; Wilson's disease or other copper-overload states (the formula supplies 2 mg copper).
CoQ10
Likely helpsA lipid-soluble antioxidant central to mitochondrial energy production, with the strongest trial support for fertility/IVF outcomes and heart failure.
Alpha-GPC
Likely helpsCrosses the blood-brain barrier to fuel acetylcholine synthesis — supports focus, memory, and power output in athletes.
Alpha Lipoic Acid
Likely helpsUniversal antioxidant that works in both water and fat, supporting blood sugar control, nerve health, and cellular energy.
Lutein + Zeaxanthin
Likely helpsCarotenoid pigments that accumulate in the eye, providing protection against blue light and age-related vision decline.
Explore: Best supplements for Body HealthBest supplements for Focus, Memory & Mood
Reviewed by Dr. Baher Al Hakim · Last reviewed July 2026 · evidence from 14 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research